Skip to Content

Madeleine Duvic, M.D.

Present Title & Affiliation

Primary Appointment

Deputy Department Chair, Department of Dermatology, Division of Internal Medicine, UTMDACC, Houston, TX
Professor of Medicine and Dermatology (with tenure), Division of Internal Medicine, UTMDACC, Houston, TX
Director of the Research Fellowship Program, Department of Dermatology, Division of Internal Medicine, UTMDACC, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Division of Epidemiology, Human Genetics & Environmental Sciences, The University of Texas School of Public Health, Houston, TX
Professor of Medicine and Dermatology, The University of Texas Medical School at Houston (UTMSH), Houston, TX

Bio Statement

Madeleine Duvic, M.D., Professor of Internal Medicine and Dermatology, is Deputy Chairman of the Department of Dermatology at The University of Texas, MD Anderson Cancer Center in Houston, Texas. She received her medical degree from Duke University Medical School and completed an internship and residencies in internal medicine and dermatology, served as chief resident, and completed a fellowship in molecular biology and geriatrics. She is a former board member of the American Academy of Dermatology and recent vice president of the Society for Investigative Dermatology. She was elected to the ADA and is a founder and board member of the United States Consortium for Cutaneous Lymphomas. She serves on Medical and Scientific Boards of the National Alopecia Areata Foundation and Cutaneous Lymphoma Foundation and is the Principal Investigator of the Alopecia Areata Registry.

Dr. Duvic has been named consistently as one of America’s Top Doctors by Castle Connolly and Best Doctors in America for 12 consecutive years. She has authored over 420 peer-reviewed journal articles, two books, and has mentored numerous medical students, residents, fellows, and PhD students.

She has been Principal Investigator of numerous clinical trials and translational research studies of T-cell mediated diseases and malignancies, including T-cell lymphomas, melanoma, and skin cancer. Her work is focused on developing and improving therapy for cutaneous T-cell lymphoma.


Clinical Interests


-     Cutaneous lymphomas and Sezary syndrome

-     Skin cancer and melanoma

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
Unit Number: 1452
Houston, TX 77030
Room Number: FCT11.6078
Phone: (713) 745-4615
Fax: (713) 745-3597

Education & Training

Degree-Granting Education

1977 Duke University Medical School, Durham, NC, MD, Medicine
1973 Rice University, Houston, TX, BA, Biology

Postgraduate Training

8/1984-6/1985 Research Visiting Fellow, Molecular Genetics, Baylor College of Medicine, Houston, TX, Dr. Thomas Caskey
7/1982-7/1984 Postdoctoral Fellowship, Molecular Genetics & Geriatrics, Duke University, Durham, NC, Drs. Russell Kaufman and Sheldon Pinnell
1981-1982 Residency in Internal Medicine, Duke University, Durham, NC
1979 Chief Resident, Dermatology, Duke University, Durham, NC
1978-1980 Residency in Dermatology, Duke University, Durham, NC
1977-1978 Internship in Internal Medicine, Duke University, Durham, NC

Board Certifications

9/1982 American Board of Internal Medicine
6/1981 American Board of Dermatology

Honors and Awards

2001-present America's Top Doctors, Castle Connolly Medical Ltd.
1994-present Best Doctors in America

Selected Publications

Peer-Reviewed Original Research Articles

1. Curry JL, Tetzlaff MT, Nicholson K, Duvic M, Kim KB, Tsai KY, Hwu WJ, Hong DS, Prieto VG, Torres-Cabala CA. Histological features associated with vemurafenib-induced skin toxicities: examination of 141 cutaneous lesions biopsied during therapy. Am J Dermatopathol 36(7):557-61, 7/2014. PMID: 24950418.
2. Talpur R, Venkatarajan S, Duvic M. Mechlorethamine gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma. Expert Rev Clin Pharmacol. e-Pub 7/2014.
3. Wang LE, Li C, Xiong P, Gershenwald JE, Prieto VG, Duvic M, Lee JE, Grimm EA, Hsu TC, Wei Q. 4-nitroquinoline-1-oxide-induced mutagen sensitivity and risk of cutaneous melanoma: a case-control analysis. Melanoma Res. e-Pub 6/2014. PMID: 24977319.
4. Dummer R, Duvic M, Scarisbrick J, Olsen EA, Rozati S, Eggmann N, Goldinger SM, Hutchinson K, Geskin L, Illidge TM, Giuliano E, Elder J, Kim YH. Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary Syndrome). Ann Oncol. e-Pub 6/2014. PMID: 24948692.
5. Kyvernitakis A, Duvic M, Mahale P, Torres HA. Interferon-Based Treatment for Patients with Mycosis Fungoides and Hepatitis C Virus Infection: A Case Series. Am J Clin Dermatol. e-Pub 6/2014. PMID: 24934807.
6. Applebaum DS, Daulat S, Duvic M. Multiple skin-colored papules with diffuse sclerosis. JAMA Dermatol. e-Pub 6/2014. PMID: 24919716.
7. Venkatarajan S, Duvic M. Sezary syndrome: an overview of current and future treatment options. Expert Opinion on Orphan Drugs 2(9). e-Pub 6/2014.
8. Gera S, Dekmezian MS, Duvic M, Tschen JA, Vega F, Cho-Vega JH. Blastic plasmacytoid dendritic cell neoplasm: Evolving insights in an aggressive hematopoietic malignancy with a predilection of skin involvement. Am J Dermatopathol 36(3):244-51, 3/2014. e-Pub 11/2013. PMID: 24247574.
9. Curry JL, Torres-Cabala CA, Kim KB, Tetzlaff MT, Duvic M, Tsai KY, Hong DS, Prieto VG. Dermatologic toxicities to targeted cancer therapy: Shared clinical and histologic adverse skin reactions. Int J Dermatol 53(3):376-84, 3/2014. e-Pub 7/2013. PMID: 23879247.
10. Talpur R, Thompson A, Gangar P, Duvic M. Pralatrexate alone or in combination with Bexarotene: Long term tolerability in relapsed/refractory mycosis fungoides. Clin Lymphoma Myeloma Leuk. e-Pub 2/2014. PMID: 24589156.
11. Querfeld C, Rosen ST, Guitart J, Duvic M, Kim YH, Dusza SW, Kuzel TM. Results of an open-label multicenter phase II trial of lenalidomide monotherapy in refractory mycosis fungoides and Sezary syndrome. Blood 123(8):1159-66, 2/2014. e-Pub 12/2013. PMID: 24335103.
12. Dreno B, Urosevic-Maiwald M, Kim Y, Guitart J, Duvic M, Dereure O, Khammari A, Knol AC, Derbij A, Lusky M, Didillon I, Santoni AM, Acres B, Bataille V, Chenard MP, Bleuzen P, Limacher JM, Dummer R. TG1042 (Adenovirus-interferon-γ) in Primary Cutaneous B-cell Lymphomas: A Phase II Clinical Trial. PLoS One 9(2):e83670, 2/2014. e-Pub 2/2014. PMCID: PMC3933342.
13. McQuitty E, Curry JL, Tetzlaff MT, Prieto VG, Duvic M, Torres-Cabala C. The differential diagnosis of CD8-positive ("type D") lymphomatoid papulosis. J Cutan Pathol 41(2):88-100, 2/2014. e-Pub 10/2013. PMID: 24118002.
14. Straus DJ, Duvic M, Horwitz SM, Hymes K, Goy A, Hernandez-Ilizaliturri FJ, Feldman T, Wegner B, Myskowski PL. Final Results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma. Ann Oncol 25(1):206-10, 1/2014. e-Pub 11/2013. PMID: 24285015.
15. Aung PP, Climent F, Muzzafar T, Curry JL, Patel KP, Servitje O, Prieto VG, Duvic M, Jaffe ES, Torres-Cabala CA. Immunophenotypic shift of CD4 and CD8 antigen expression in primary cutaneous T-cell lymphomas: a clinicopathologic study of three cases. J Cutan Pathol 41(1):51-7, 1/2014. e-Pub 11/2013. PMID: 24151865.
16. Vin H, Ching G, Ojeda SS, Adelmann CH, Chitsazzadeh V, Dwyer DW, Ma H, Ehrenreiter K, Baccarini M, Ruggieri R, Curry JL, Ciurea AM, Duvic M, Busaidy NL, Tannir NM, Tsai KY. Sorafenib suppresses JNK-dependent apoptosis through inhibition of ZAK. Mol Cancer Ther 13(MCT-13-0561R):221-9, 1/2014. e-Pub 10/2013. PMID: 24170769.
17. Duvic M, Martin AG, Olsen EA, Fivenson DP, Prince HM. Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma. Leuk Lymphoma 54(3):514-9, 3/2013. e-Pub 9/2012. PMID: 22891708.
18. Jahan-Tigh RR, Huen AO, Lee GL, Pozadzides JV, Liu P, Duvic M. Hydrochlorothiazide and cutaneous T-cell lymphoma: Prospective analysis and case series. Cancer 119(4):825-31, 2/2013. e-Pub 9/2012. PMID: 22952039.
19. Duvic M, Dummer R, Becker JC, Poulalhon N, Ortiz Romero P, Grazia Bernengo M, Lebbé C, Assaf C, Squier M, Williams D, Marshood M, Tai F, Prince HM. Panobinostat activity in both bexarotene-exposed and -naďve patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial. Eur J Cancer 49(2):386-94, 1/2013. e-Pub 9/2012. PMID: 22981498.
20. Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Straus DJ. Incidence of spontaneous remission in patients with CD25-positive mycosis fungoides/Sézary syndrome receiving placebo. J Am Acad Dermatol 67(5):867-75, 11/2012. e-Pub 1/2012. PMID: 22285675.
21. Garcia-Uribe A, Zou J, Duvic M, Cho-Vega JH, Prieto VG, Wang LV. In vivo diagnosis of melanoma and non-melanoma skin cancer using oblique incidence diffuse reflectance spectrometry. Cancer Res 72(11):2738-45, 6/2012. e-Pub 4/2012. PMCID: PMC3367032.
22. Talpur R, Duvic M. Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral T-cell lymphomas. Clin Lymphoma Myeloma Leukemia 12(3):180-185, 6/2012.
23. Horwitz SM, Kim YH, Foss F, Zain JM, Myskowski PL, Lechowicz MJ, Fisher DC, Shustov AR, Bartlett NL, Delioukina ML, Koutsoukos T, Saunders ME, O'Connor OA, Duvic M. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Blood 119(18):4115-22, 5/2012. e-Pub 3/2012. PMID: 22394596.
24. Kempf W, Pfaltz K, Vermeer MH, Cozzio A, Ortiz-Romero PL, Bagot M, Olsen E, Kim YH, Dummer R, Pimpinelli N, Whittaker S, Hodak E, Cerroni L, Berti E, Horwitz S, Prince HM, Guitart J, Estrach T, Sanches JA, Duvic M, Ranki A, Dreno B, Ostheeren-Michaelis S, Knobler R, Wood G, Willemze R. European Organization for Research and Treatment of Cancer (EORTC), International Society of Cutaneous Lymphoma (ISCL) and United States Cutaneous Lymphoma Consortium (USCLC) consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood 118(15):4024-35, 10/2011. e-Pub 8/2011. PMCID: PMC3204726.
25. Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, Wood GS, Willemze R, Demierre MF, Pimpinelli N, Bernengo MG, Ortiz-Romero PL, Bagot M, Estrach T, Guitart J, Knobler R, Sanches JA, Iwatsuki K, Sugaya M, Dummer R, Pittelkow M, Hoppe R, Parker S, Geskin L, Pinter-Brown L, Girardi M, Burg G, Ranki A, Vermeer M, Horwitz S, Heald P, Rosen S, Cerroni L, Dreno B, Vonderheid EC. Clinical end points and response criteria in mycosis fungoides and sezary syndrome: a consensus statement of the international society for cutaneous lymphomas, the United States cutaneous lymphoma consortium, and the cutaneous lymphoma task force of the European organization for research and treatment of cancer. J Clin Oncol 29(18):2598-607, 6/2011. e-Pub 5/2011. PMCID: PMC3422534.
26. Talpur R, Demierre MF, Geskin L, Baron E, Pugliese S, Eubank K, Zic JA, Miller DR, Tharp M, Bohjanen K, Duvic M. Multicenter photopheresis intervention trial in early stage mycosis fungoides. Clin Lymphoma Myeloma Leuk 11(2):219-27, 4/2011. e-Pub 4/2011. PMID: 21575927.
27. Olsen EA, Rook AH, Zic J, Kim Y, Porcu P, Querfeld C, Wood G, Demierre MF, Pittelkow M, Wilson LD, Pinter-Brown L, Advani R, Parker S, Kim EJ, Junkins-Hopkins JM, Foss F, Cacchio P, Duvic M. Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol 64(2):352-404, 2/2011. e-Pub 12/2010. PMID: 21145619.
28. Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, Scarisbrick J, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Kim YH. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 28(29):4485-91, 10/2010. e-Pub 8/2010. PMID: 20697094.
29. Duvic M, Donato M, Dabaja B, Richmond H, Singh L, Wei W, Acholonu S, Khouri I, Champlin R, Hosing C. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and sezary syndrome. J Clin Oncol 28(14):2365-72, 5/2010. e-Pub 3/2010. PMID: 20351328.
30. Kunishige JH, McDonald H, Alvarez G, Johnson M, Prieto V, Duvic M. Lymphomatoid papulosis and associated lymphomas: A retrospective case series of 84 patients. Clin Exp Dermatol 34(5):576-81, 7/2009. e-Pub 1/2009. PMID: 19196298.
31. Vidulich KA, Talpur R, Bassett RL, Duvic M. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma. Int J Dermatol 48(3):243-52, 3/2009. PMID: 19261011.
32. Sun G, Berthelot C, Li Y, Glass DA, George D, Pandya A, Kurzrock R, Duvic M. Poor prognosis in non-Caucasian patients with early-onset mycosis fungoides. J Am Acad Dermatol 60(2):231-5, 2/2009. e-Pub 11/2008. PMID: 19026464.
33. Li C, Zhao H, Hu Z, Liu Z, Wang LE, Gershenwald JE, Prieto VG, Lee JE, Duvic M, Grimm EA, Wei Q. Genetic variants and haplotypes of the caspase-8 and caspase-10 genes contribute to susceptibility to cutaneous melanoma. Hum Mutat 29(12):1443-1451, 12/2008. PMCID: PMC2937220.
34. Zhang C, Li B, Gaikwad AS, Haridas V, Xu Z, Gutterman JU, Duvic M. Avicin D Selectively Induces Apoptosis and Downregulates p-STAT-3, bcl-2, and Survivin in Cutaneous T-Cell Lymphoma Cells. J Invest Dermatol 128(11):2728-35, 11/2008. e-Pub 5/2008. PMID: 18496567.
35. Ni X, Richmond HM, Liao XM, Decker WK, Shiue LH, Shpall EJ, Duvic M. Induction of T-Cell responses against cutaneous T-Cell lymphomas ex vivo by autologous dendritic cells transfected with amplified tumor mRNA. J Invest Dermatol 128(11):2631-9, 11/2008. e-Pub 5/2008. PMID: 18480841.
36. Senff NJ, Noordijk EM, Kim YH, Bagot M, Berti E, Cerroni L, Dummer R, Duvic M, Hoppe RT, Pimpinelli N, Rosen ST, Vermeer MH, Whittaker S, Willemze R, Willemze R, Willemze R. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 112(5):1600-9, 9/2008. PMID: 18567836.
37. Talpur R, Bassett R, Duvic M. Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sezary syndrome. Br J Dermatol 159(1):105-12, 7/2008. PMID: 18489588.
38. Li C, Liu Z, Wang LE, Gershenwald JE, Lee JE, Prieto VG, Duvic M, Grimm EA, Wei Q. Haplotype and genotypes of the VDR gene and cutaneous melanoma risk in non-Hispanic whites in Texas: a case-control study. Int J Cancer 122(9):2077-84, 5/2008. PMCID: PMC2938035.
39. Brownell I, Etzel CJ, Yang DJ, Taylor SH, Duvic M. Increased malignancy risk in the cutaneous T-cell lymphoma patient population. Clin Lymphoma Myeloma 8(2):100-5, 4/2008. PMID: 18501103.
40. Horwitz SM, Olsen EA, Duvic M, Porcu P, Kim YH. Review of the treatment of mycosis fungoides and Sezary syndrome: a stage-based approach. J Natl Compr Canc Netw 6(4):436-42, 4/2008. PMID: 18433609.
41. Leitenberger JJ, Berthelot CN, Polder KD, Pro B, McLaughlin P, Jones D, Duvic M. CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor with response to pralatrexate. J Am Acad Dermatol 58(3):480-4, 3/2008. PMID: 18280345.
42. Kalsotra A, Du L, Wang Y, Ladd PA, Kikuta Y, Duvic M, Boyd AS, Keeney DS, Strobel HW. Inflammation resolved by retinoid X receptor-mediated inactivation of leukotriene signaling pathways. FASEB J 22(2):538-47, 2/2008. PMID: 17884973.
43. Duvic M. EGFR inhibitor-associated acneiform folliculitis: assessment and management. Am J Clin Dermatol 9(5):285-94, 2008. PMID: 18717603.
44. Duvic M, Foss FM. Mycosis fungoides: pathophysiology and emerging therapies. Semin Oncol 34(6 Suppl 5):S21-8, 12/2007. PMID: 18086343.
45. Wang LE, Li C, Strom SS, Goldberg LH, Brewster A, Guo Z, Qiao Y, Clayman GL, Lee JJ, El-Naggar AK, Prieto VG, Duvic M, Lippman SM, Weber RS, Kripke ML, Wei Q. Repair capacity for UV light induced DNA damage associated with risk of nonmelanoma skin cancer and tumor progression. Clin Cancer Res 13(21):6532-9, 11/2007. PMID: 17975167.
46. Shin J, Monti S, Aires DJ, Duvic M, Golub T, Jones DA, Kupper TS. Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome. Blood 110(8):3015-27, 10/2007. e-Pub 7/2007. PMCID: PMC2018675.
47. Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, Zackheim H, Duvic M, Estrach T, Lamberg S, Wood G, Dummer R, Ranki A, Burg G, Heald P, Pittelkow M, Bernengo MG, Sterry W, Laroche L, Trautinger F, Whittaker S. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110(6):1713-22, 9/2007. e-Pub 5/2007. PMID: 17540844.
48. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Duvic M. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25(21):3109-15, 7/2007. e-Pub 6/2007. PMID: 17577020.
49. Kim YH, Duvic M, Obitz E, Gniadecki R, Iversen L, Osterborg A, Whittaker S, Illidge TM, Schwarz T, Kaufmann R, Cooper K, Knudsen KM, Lisby S, Baadsgaard O, Knox SJ. Clinical efficacy of zanolimumab (HuMax-CD4): two Phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 109(11):4655-4662, 6/2007. PMID: 17311990.
50. Straus DJ, Duvic M, Kuzel T, Horwitz S, Demierre MF, Myskowski P, Steckel S. Results of a Phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma. Cancer 109(9):1799-1803, 5/2007. e-Pub 3/2007. PMID: 17366595.
51. Baser S, Onn A, Lin E, Morice RC, Duvic M. Pulmonary manifestations in patients with cutaneous T-cell lymphomas. Cancer 109(8):1550-1555, 3/2007. PMID: 17351938.
52. Li C, Liu Z, Zhang Z, Strom SS, Gershenwald JE, Prieto VG, Lee JE, Ross MI, Mansfield PF, Cormier JN, Duvic M, Grimm EA, Wei Q. Genetic variants of the vitamin D receptor gene alter risk of cutaneous melanoma. J Invest Dermatol 127:276-80, 2/2007. e-Pub 9/2006. PMID: 16990805.
53. Martinez-Mir A, Zlotogorski A, Gordon D, Petukhova L, Mo J, Gilliam TC, Londono D, Haynes C, Ott J, Hordinsky M, Nanova K, Norris D, Price V, Duvic M, Christiano AM. Genomewide scan for linkage reveals evidence of several susceptibility loci for alopecia areata. Am J Hum Genet 80:316-28, 2/2007. PMCID: PMC1785354.
54. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, Frankel SR. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109(1):31-9, 1/2007. e-Pub 9/2006. PMCID: PMC1785068.
55. Duvic M, Sherman ML, Wood GS, Kuzel TM, Olsen E, Foss F, Laliberte RJ, Ryan JL, Zonno K, Rook AH. A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides. J Am Acad Dermatol 55(5):807-13, 11/2006. e-Pub 8/2006. PMID: 17052486.
56. Doherty SD, Prieto VG, George S, Hazarika P, Duvic M. High flotillin-2 expression is associated with lymph node metastasis and Breslow depth in melanoma. Melanoma Res 16:461-463, 10/2006. PMID: 17013097.
57. Duvic M, Talpur R, Wen S, Kurzrock R, David CL, Apisarnthanarax N. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma 7(1):51-58, 7/2006. PMID: 16879770.
58. Li C, Larson D, Zhang Z, Liu Z, Strom SS, Gershenwald JE, Prieto VG, Lee JE, Ross MI, Mansfield PF, Cormier JN, Duvic M, Grimm EA, Wei Q. Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. Pharmacogenet Genomics 16(4):253-63, 4/2006. PMID: 16538172.
59. Talpur R, Jones DM, Alencar AJ, Apisarnthanarax N, Herne KL, Yang Y, Duvic M. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma. J Invest Dermatol 126(3):575-83, 3/2006. PMID: 16410787.
60. Donato ML, Feasel AM, Weber DM, Prieto VG, Giralt SA, Champlin RE, Duvic M. Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation. Blood 107(2):463-6, 1/2006. e-Pub 9/2005. PMCID: PMC1895605.
61. Zhang C, Richon V, Ni X, Talpur R, Duvic M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: Relevance to mechanism of therapeutic action. J Invest Dermatol 125(5):1045-52, 11/2005. PMID: 16297208.
62. Hazarika P, McCarty MF, Prieto VG, George S, Babu D, Koul D, Bar-Eli M, Duvic M. Up-regulation of Flotillin-2 is associated with melanoma progression and modulates expression of the thrombin receptor protease activated receptor 1. Cancer Res 64(20):7361-9, 10/2004. PMID: 15492257.
63. Zhang C, Ni X, Konopleva M, Andreeff M, Duvic M. The novel synthetic oleanane triterpenoid CDDO (2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid) induces apoptosis in Mycosis fungoides/Sezary syndrome cells. J Invest Dermatol 123(2):380-7, 8/2004. PMID: 15245439.
64. Apisarnthanarax N, Talpur R, Ward S, Ni X, Kim HW, Duvic M. Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study. J Am Acad Dermatol 50(4):600-7, 4/2004. PMID: 15034511.
65. Duvic M, Ni X, Talpur R, Herne K, Schulz C, Sui D, Ward S, Joseph A, Hazarika P. Tazarotene-induced gene 3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene application. J Invest Dermatol 121(4):902-9, 10/2003. PMID: 14632211.
66. Duvic M, Apisarnthanarax N, Cohen DS, Smith TL, Ha CS, Kurzrock R. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 49(1):35-49, 7/2003. PMID: 12833006.
67. Duvic M, Chiao N, Talpur R. Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma. J Cutan Med Surg 7(4 Suppl):3-7, 7/2003. PMID: 12958700.
68. Herne KL, Talpur R, Breuer-McHam J, Champlin R, Duvic M. Cytomegalovirus seropositivity is significantly associated with mycosis fungoides and Sezary syndrome. Blood 101(6):2132-6, 3/2003. e-Pub 11/2002. PMID: 12446446.
69. Apisarnthanarax N, Donato M, Korbling M, Couriel D, Gajewski J, Giralt S, Khouri I, Hosing C, Champlin R, Duvic M, Anderlini P. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results. Bone Marrow Transplant 31(6):459-65, 3/2003. PMID: 12665841.
70. Zhang C, Duvic M. Retinoids: therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma. Dermatol Ther 16(4):322-30, 2003. PMID: 14686975.
71. Washington LT, Huh YO, Powers LC, Duvic M, Jones D. A stable aberrant immunophenotype characterizes nearly all cases of cutaneous T-cell lymphoma in blood and can be used to monitor response to therapy. BMC Clin Pathol 2(1):5, 12/2002. PMCID: PMC140025.
72. Vega F, Luthra R, Medeiros LJ, Dunmire V, Lee SJ, Duvic M, Jones D. Clonal heterogeneity in mycosis fungoides and its relationship to clinical course. Blood 100(9):3369-73, 11/2002. PMID: 12384439.
73. Talpur R, Lifshitz O, Breuer-Mcham J, Duvic M. Increased serum immunoglobulin levels are common in mycosis fungoides and Sezary syndrome. J Am Acad Dermatol 47(5):685-91, 11/2002. PMID: 12399759.
74. Morgan M, Maloney D, Duvic M. Hypomagnesemia and hypocalcemia in mycosis fungoides: a retrospective case series. Leuk Lymphoma 43(6):1297-302, 6/2002. PMID: 12152999.
75. Zhang C, Hazarika P, Ni X, Weidner DA, Duvic M. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res 8(5):1234-1240, 5/2002. PMID: 12006543.
76. Breuer-McHam J, Simpson E, Dougherty I, Bonkobara M, Ariizumi K, Lewis DE, Dawson DB, Duvic M, Cruz PD, Jr. Activation of HIV in human skin by ultraviolet B radiation and its inhibition by NFkappaB blocking agents. Photochem Photobiol 74(6):805-10, 12/2001. PMID: 11783936.
77. Jones D, Dang NH, Duvic M, Washington LT, Huh YO. Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. Am J Clin Pathol 115(6):885-92, 6/2001. PMID: 11392886.
78. Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, Crowley C, Yocum RC. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 19(9):2456-71, 5/2001. PMID: 11331325.
79. Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, Yocum RC. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 137(5):581-93, 5/2001. PMID: 11346336.
80. Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, Jegasothy B, Wood G, Gordon M, Heald P, Oseroff A, Pinter-Brown L, Bowen G, Kuzel T, Fivenson D, Foss F, Glode M, Molina A, Knobler E, Stewart S, Cooper K, Stevens S, Craig F, Reuben J, Bacha P, Nichols J. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19(2):376-88, 1/2001. PMID: 11208829.
81. Duvic M, Helekar B, Schulz C, Cho M, DiSepio D, Hager C, DiMao D, Hazarika P, Jackson B, Breuer-McHam J, Young J, Clayman G, Lippman SM, Chandraratna RA, Robinson NA, Deucher A, Eckert RL, Nagpal S. Expression of a retinoid-inducible tumor suppressor, Tazarotene-inducible gene-3, is decreased in psoriasis and skin cancer. Clin Cancer Res 6(8):3249-59, 8/2000. PMID: 10955811.
82. Hazarika P, Dham N, Patel P, Cho M, Weidner D, Goldsmith L, Duvic M. Flotillin 2 is distinct from epidermal surface antigen (ESA) and is associated with filopodia formation. J Cell Biochem 75(1):147-59, 10/1999. PMID: 10462713.
83. Sherman SI, Gopal J, Haugen BR, Chiu AC, Whaley K, Nowlakha P, Duvic M. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med 340(14):1075-9, 4/1999. PMID: 10194237.
84. DiSepio D, Ghosn C, Eckert RL, Deucher A, Robinson N, Duvic M, Chandraratna RA, Nagpal S. Identification and characterization of a retinoid-induced class II tumor suppressor/growth regulatory gene. Proc Natl Acad Sci U S A 95(25):14811-5, 12/1998. PMCID: PMC24531.
85. Diamandidou E, Colome-Grimmer M, Fayad L, Duvic M, Kurzrock R. Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. Blood 92(4):1150-9, 8/1998. PMID: 9694702.
86. Jackow C, Puffer N, Hordinsky M, Nelson J, Tarrand J, Duvic M. Alopecia areata and cytomegalovirus infection in twins: genes versus environment? J Am Acad Dermatol 38(3):418-25, 3/1998. PMID: 9520023.
87. Duvic M, Nagpal S, Asano AT, Chandraratna RA. Molecular mechanisms of tazarotene action in psoriasis. J Am Acad Dermatol 37(2 Pt 3):S18-24, 8/1997. PMID: 9270552.
88. Nagpal S, Patel S, Jacobe H, DiSepio D, Ghosn C, Malhotra M, Teng M, Duvic M, Chandraratna RA. Tazarotene-induced gene 2 (TIG2), a novel retinoid-responsive gene in skin. J Invest Dermatol 109(1):91-5, 7/1997. PMID: 9204961.
89. Sarris AH, Daliani D, Ulmer R, Crow M, Broxmeyer HE, Reiss M, Karasavvas N, Zelenetz AD, Pugh W, Cabanillas F, Deisseroth AB, Duvic M. Interferon-inducible protein 10 as a possible factor in the pathogenesis of cutaneous T-cell lymphomas. Clin Cancer Res 3(2):169-77, 2/1997. PMID: 9815669.
90. Jackow CM, Cather JC, Hearne V, Asano AT, Musser JM, Duvic M. Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansion. Blood 89(1):32-40, 1/1997. PMID: 8978274.
91. Konstantinova NV, Duong DM, Remenyik E, Hazarika P, Chuang A, Duvic M. Interleukin-8 is induced in skin equivalents and is highest in those derived from psoriatic fibroblasts. J Invest Dermatol 107(4):615-21, 10/1996. PMID: 8823370.
92. Duvic M, Hester JP, Lemak NA. Photopheresis therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 35(4):573-9, 10/1996. PMID: 8859287.
93. Jackow CM, McHam JB, Friss A, Alvear J, Reveille JR, Duvic M. HLA-DR5 and DQB1*03 class II alleles are associated with cutaneous T-cell lymphoma. J Invest Dermatol 107(3):373-6, 9/1996. PMID: 8751973.
94. Duvic M, Lemak NA, Redman JR, Eifel PJ, Tucker SL, Cabanillas FF, Kurzrock R. Combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 34(6):1022-9, 6/1996. PMID: 8647968.
95. Nagpal S, Patel S, Asano AT, Johnson AT, Duvic M, Chandraratna RA. Tazarotene-induced gene 1 (TIG1), a novel retinoic acid receptor-responsive gene in skin. J Invest Dermatol 106(2):269-74, 2/1996. PMID: 8601727.
96. Sarris AH, Luthra R, Papadimitracopoulou V, Waasdorp M, Dimopoulos MA, McBride JA, Cabanillas F, Duvic M, Deisseroth A, Morris SW, Pugh WC. Amplification of genomic DNA demonstrates the presence of the t(2;5) (p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. Blood 88(5):1771-9, 1/1996. PMID: 8781434.
97. Sarris AH, Esgleyes-Ribot T, Crow M, Broxmeyer HE, Karasavvas N, Pugh W, Grossman D, Deisseroth A, Duvic M. Cytokine loops involving interferon-gamma and IP-10, a cytokine chemotactic for CD4+ lymphocytes: an explanation for the epidermotropism of cutaneous T-cell lymphoma? Blood 86(2):651-8, 7/1995. PMID: 7605995.
98. Cho YJ, Chema D, Moskow JJ, Cho M, Schroeder WT, Overbeek P, Buchberg AM, Duvic M. Epidermal surface antigen (MS17S1) is highly conserved between mouse and human. Genomics 27(2):251-8, 5/1995. PMID: 7557989.
99. Welsh EA, Clark HH, Epstein SZ, Reveille JD, Duvic M. Human leukocyte antigen-DQB1*03 alleles are associated with alopecia areata. J Invest Dermatol 103(6):758-63, 12/1994. PMID: 7798612.
100. Schroeder WT, Stewart-Galetka S, Mandavilli S, Parry DA, Goldsmith L, Duvic M. Cloning and characterization of a novel epidermal cell surface antigen (ESA). J Biol Chem 269(31):19983-91, 8/1994. PMID: 8051082.
101. Duvic M, Nelson DC, Annarella M, Cho M, Esgleyes-Ribot T, Remenyik E, Ulmer R, Rapini RP, Sacks PG, Clayman GL, Davies PJA, Thacher S. Keratinocyte transglutaminase expression varies in squamous cell carcinomas. J Invest Dermatol 102(4):462-9, 4/1994. PMID: 7908683.
102. Kayes LM, Schroeder WT, Marchuk DA, Collins FS, Riccardi VM, Duvic M, Stephens K. The gene for a novel epidermal antigen maps near the neurofibromatosis 1 gene. Genomics 14(2):369-76, 10/1992. PMID: 1358802.
103. Schroeder WT, Thacher SM, Stewart-Galetka S, Annarella M, Chema D, Siciliano MJ, Davies PJ, Tang HY, Sowa BA, Duvic M. Type I keratinocyte transglutaminase: expression in human skin and psoriasis. J Invest Dermatol 99(1):27-34, 7/1992. PMID: 1351505.
104. Schroeder WT, Siciliano MJ, Stewart-Galetka SL, Duvic M. The human gene for an epidermal surface antigen (M17S1) is located at 17q11-12. Genomics 11(2):481-2, 10/1991. PMID: 1769667.
105. Durland RH, Kessler DJ, Gunnell S, Duvic M, Pettitt BM, Hogan ME. Binding of triple helix forming oligonucleotides to sites in gene promoters. Biochemistry 30(38):9246-55, 9/1991. PMID: 1892832.
106. Mahoney SE, Duvic M, Nickoloff BJ, Minshall M, Smith LC, Griffiths CE, Paddock SW, Lewis DE. Human immunodeficiency virus (HIV) transcripts identified in HIV-related psoriasis and Kaposi's sarcoma lesions. J Clin Invest 88(1):174-85, 7/1991. PMID: 1676036.
107. Konohana A, Konohana I, Schroeder WT, O'Brien WR, Amagai M, Greer J, Shimizu N, Gammon WR, Siciliano MJ, Duvic M. Placental glutathione-S-transferase-pi mRNA is abundantly expressed in human skin. J Invest Dermatol 95(2):119-26, 8/1990. PMID: 2380573.
108. Stoler A, Kopan R, Duvic M, Fuchs E. Use of monospecific antisera and cRNA probes to localize the major changes in keratin expression during normal and abnormal epidermal differentiation. J Cell Biol 107(2):427-46, 8/1988. PMCID: PMC2115222.

Book Chapters

1. Duvic M. Cutaneous T-cell lymphomas: Mycosis fungoides and sezary syndrome. In: Lymphoma: Diagnosis and Treatment. Ed(s) Younes A, Coiffier B. Springer: New York, 287-329, 2013. ISBN: 978-1-62703-407-4.

Books (edited and written)

1. Vahquist A, Duvic M. Ed(s) Taylor & Frances. Retinoids and Carotenoids in Dermatology. Taylor & Frances, 2007.
2. Werth VP, Duvic M. Dermatologic Clinics on Medical Dermatology. WB Saunders, Inc., 2001.
3. Duvic M. The use of retinoids in Dermatology - Duvic M. Ed Tharp, M. In Therapy, Munksgaard, Copenhagen. 7: Copenhagen, 1998.

Letters to the Editor

1. Nadeem S, Hymes S, Kebriaei P, Abruzzo L, Curry JL, Duvic M. Alopecia areata after HLA-identical BMT from an affected, sibling donor. Bone Marrow Transplant, 2/2014. e-Pub 1/2014. PMID: 24442249.
2. Foss F, Duvic M, Olsen EA. Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma. Am J Hematol 86(7):627-30, 7/2011. e-Pub 6/2011. PMID: 21674574.
3. Petukhova L, Duvic M, Hordinsky M, Norris D, Price V, Shimomura Y, Kim H, Singh P, Lee A, Chen WV, Meyer KC, Paus R, Jahoda CA, Amos CI, Gregersen PK, Christiano AM. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature 466(7302):113-7, 7/2010. PMCID: PMC2921172.
4. Li C, Chen K, Liu Z, Wang LE, Gershenwald JE, Lee JE, Prieto VG, Duvic M, Grimm EA, Wei Q. Polymorphisms of TP53 Arg72Pro, but not p73 G4C14>A4TA4 and p21 Ser31Arg, contribute to risk of cutaneous melanoma. J Invest Dermatol 128(6):1585-8, 6/2008. e-Pub 11/2007. PMCID: PMC2938047.
5. Duvic M, Grossman D. More on acyclovir for chickenpox. N Engl J Med 331(1):59, 7/1994. PMID: 8202117.
6. Duvic M, Rios A, Brewton GW. Remission of AIDS-associated psoriasis with zidovudine. Lancet 2(8559):627, 9/1987. PMID: 2887910.
7. Johnson TM, Duvic M, Rapini RP, Rios A. AIDS exacerbates psoriasis. N Engl J Med 313(22):1415, 11/1985. PMID: 4058535.

Last updated: 7/29/2014